Janssen COVID-19 Vaccine (Johnson & Johnson)

Janssen COVID-19 Vaccine (Johnson & Johnson): Effective April 23, 2021, CDC and FDA recommend that use of the Janssen COVID-19 Vaccine resume in the United States. However, women younger than 50 years old especially should be made aware of a rare risk of blood clots with low platelets following vaccination and the availability of other COVID-19 vaccines where this risk has not been observed. Read the CDC/FDA statement.

Learn more:

Summary of Recent Changes and Updates

Webpage content and individual PDFs are updated when there’s new guidance concerning the Janssen (Johnson & Johnson) COVID-19 vaccine. Expand each section below to see a summary of new and updated items spanning the past month.

General J&J/Janssen Vaccine Information
Administration Overview

Before administering vaccine, screen recipients for contraindications and precautions.

To assess patients correctly and consistently, vaccination providers should use a standardized, comprehensive screening tool.

Contraindications and Precautions
How to Prepare and Administer the Janssen Vaccine
clipboard list check icon

laptop solid icon
Document the Vaccination

COVID-19 vaccination providers must document vaccine administration in their medical record systems within 24 hours of administration and use their best efforts to report administration data to the relevant system for the jurisdiction (i.e., immunization information system) as soon as practicable and no later than 72 hours after administration.

Storage and Handling Overview
weather icon

Store vaccine in a refrigerator. Do not freeze.

The vaccine will arrive at a refrigerated temperature of 2°C to 8°C (36°F and 46°F).

  • Unpack the vaccine shipment following the manufacturer’s directions.
    • Check both temperature monitoring devices in the box (3M MonitorMark and FreezeMark).
  • An ancillary supply kit will arrive separately from the vaccine.
How to Store the Janssen COVID-19 Vaccine
comment alt lines light icon
Report Adverse Events

Adverse events that occur in a recipient after COVID-19 vaccination are required to be reported to the Vaccine Adverse Event Reporting System (VAERS). FDA requires vaccination providers to report vaccine administration errors, serious adverse events, cases of multisystem inflammatory syndrome, and cases of COVID-19 that result in hospitalization or death after administration of COVID-19 vaccine under an EUA. Reporting is encouraged for other clinically significant adverse events, even if it is not clear that a vaccine caused the adverse event. Complete and submit reports to VAERS onlineexternal icon.

For further assistance with reporting to VAERS, call 1-800-822-7967.

hand holding medical light icon
What to Expect after a COVID-19 Vaccination

Print informationpdf icon for your patients on common side effects, helpful tips, and when to call a doctor after a COVID-19 vaccination.

email_03Get Email Updates

To receive email updates about this page, enter your email address:

Page last reviewed: August 10, 2021